Professor Innocenti serves as the Chair of the Gastrointestinal Solid Tumor Correlative Science Group in the Alliance for Clinical Trials in Oncology (previously, Cancer and Leukemia Group B). He is also the Translational Science Representative of the NCI Colon Task Force of the Gastrointestinal Steering Committee.
Professor Innocenti has published more than 150 peer-reviewed publications and book chapters in clinical pharmacology, pharmacogenomics, and oncology. Major findings from landmark studies and seminal discoveries have been reported in the Journal of Clinical Oncology, JAMA, Cell, Clinical Pharmacology and Therapeutics, Clinical Cancer Research, Nature Genetics and other noteworthy journals. He is the editor of five books in pharmacogenomics and oncology. Professor Innocenti sits on the editorial board of Clinical Pharmacology and Therapeutics, and Pharmacogenetics and Genomics, among other journals. He is the Associate Editor for Pharmacogenomics.
Professor Innocenti received the Leon I Goldberg Young Investigator Award from the American Society of Clinical Pharmacology and Therapeutics in 2012, as well as a Young Investigator Award from the Cancer Research Foundation in 2006. He has received the National Scientific Qualification as Full Professor of Pharmacology, Clinical Pharmacology, and Pharmacognosy from Italy in 2014. Professor Innocenti is frequently invited to speak internationally on the topics of precision medicine and genomics in oncology. He has organized several international symposia and meetings on genomic and translational medicine and has chaired the Oncology Section of the American Society of Clinical Pharmacology and Therapeutics.
Among Professor Innocenti’s exemplary achievements is the elucidation of the genetic basis of severe neutropenia in cancer patients treated with irinotecan, a poster child for pharmacogenetics. Dr. Innocenti is the co-inventor of the FDA-approved UGT1A1 genetic test for patients treated with irinotecan. As a result of this pioneering work, the labeling of irinotecan has since been revised.
Professor Innocenti’s NIH-funded program applies genomic technologies to discover novel determinants of efficacy and safety of cancer therapy. This research aims to achieve the goal of precision therapy in oncology through the selection of the most effective treatment regimen for any given patient.
PGRN Hub & the Featured Investigator